Show/hide main menu

Events

DIIID Seminar: Dr Javed N Agrewala

When
30/09/2014 (12:15-13:15)
Contact

Denise Jamieson

Description

Location: Gowland HopkinsLecture Theatre, Hodgkin Building, Guy's Campus

THIS SEMINAR HAS BEEN CANCELLED

Induction of the activation of innate and adaptive immunity by lipidated peptide vaccine: robust and enduring protective memory Th17 cells against Mycobacterium tuberculosis

Speaker: Dr Javed N Agrewala, CSIR-Institute of Microbial Technology

Abstract: In tuberculosis-endemic population, the main reason for the failure of BCG vaccine is the obstacle caused by non-tuberculous mycobacteria and helminths in its processing and presentation. Usually, peptides do not require extensive antigen processing, since they can bind to major histocompatibility complex molecules and therefore can be directly presented to T cells. As a result, peptide vaccines can surmount the problems associated with BCG failure. It is well-established fact that not only adaptive but also innate immunity plays a crucial role in protection against tuberculosis. Hence we have constructed a novel lipopeptide vaccine by linking promiscuous CD4 and CD8 epitopes of Mycobacterium tuberculosis to Pam2Cys, a Toll Like Receptor-2 agonist. This lipopeptide has unique property of self-adjuvanting and concurrently activating both innate and adaptive immunity. The vaccine can be targeted to dendritic cells and it binds directly to MHC I and MHC II molecules and TLR-2. It stimulates dendritic cells to secrete cytokines, upregulates the expression of costimulatory molecules and significantly augments their ability to present antigen to T cells. Further, the vaccinated animals impart robust and enduring memory Th1 and Th17 response. The protection observed is significantly better than BCG. This lipidated-peptide vaccine is unique since it overcomes MHC barriers and evokes immune response irrespective of HLA polymorphism in human. This vaccine has enough potential to induce long-lasting protection against Mycobacterium tuberculosis. Therefore, can be a potent future vaccine candidate for controlling tuberculosis.

See more from the Division of Immunology, Infection & Inflammatory Disease Seminar Series.

Event Highlights:

Sorry, there are no current events
Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454